OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

Condition(s) studied

Investigational drug(s) / intervention(s)

Ovarian function suppression with endocrine treatments: * Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years. * Either goserelin acetate or leuprorelin Acetate is allowed. * These patients are able to choose bilateral salpingo-oophorectomy instead of OFS. * Chemotherapy is omitted in these patients.

Study summary

Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®).

In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.

Eligibility

Primary outcome measure(s)

• Distant recurrence-free survival — 5-years distant recurrence-free survival
  The interval between the date of primary surgery and the date of last censored, or distant recurrence or death of any cause

Trial sites (2)

More Gangnam Severance Hospital trials in South Korea

Other trials for the same condition